IDIBELL Licenses to Janus a Patent for the Treatment of Immune Diseases
News Dec 06, 2012
The Bellvitge Biomedical Research Institute (IDIBELL) has signed a licensing agreement with the company Janus Developments of a patent for an immunomodulatory product for treating immune diseases such as autoimmune diseases, sepsis, hypersensitivity disorders (including, allergic reactions) or post-transplant rejection. The patent has been developed by the researcher of the Human Molecular Genetics group Josep Maria Aran and his team.
The invention relates to a concrete form of C4BP protein (C4b-binding protein), which is able to inhibit other proteins in the complement system, a major component of the innate immune response.
Step into the market
Many years will be needed before the product developed by Dr. Aran can be applied in humans. It will require additional preclinical studies and clinical trials in humans. In this sense, the signing of the license agreement is an important step to complete these studies and to become in the future a pharmaceutical product.
The head of the Technology Transfer Office (TTO) at IDIBELL, Montse Ballarín, highlights the fact that "the license products developed at our institution reflects the IDIBELL strategy as a public research centre, to bring our ideas and inventions to market."
Ballarín stresses that the transfer of a technology or a product to industry is not an easy process. "You have to offer a good product that meets a market need, to solve an unsolved problem, a technically and economically feasible production, a will to buy by the health system and a long list of conditions that are overcome before to achieve the interest of the company." Finally, "there is a good bargain to adequately protect the interests of inventors and the institution", explains the OTRI responsible.
Janus Developments is a company dedicated to biomedical knowledge transfer to the market. Currently develop eleven projects based on patents originated at several universities and research centres. In addition, Janus timely collaborates in defining and implementing various companies and foundations. Janus Developments supports IDIBELL in transfer activities, from identifying technologies to the introduction to market.
The license signed with Janus is the first patent that IDIBELL, through its TTO, has been transferred to a company outside the campus (previously had managed licensing contracts with spin-offs arising from the institution). Also recently it has been transferred a diagnostic technology and a patent to a multinational pharmaceutical company. At this time, IDIBELL is on track to close two licensing agreements over two patents developed by researchers at the centre.
Blood Cancers are Outsmarting the Immune System, But How?News
Researchers have discovered how some of the blood cancers known as myeloproliferative neoplasms (MPNs) evade the immune system.READ MORE
Can You Eat Cells? Computer Model Predicts Organisms that Use PhagocytosisNews
A computer model developed by Museum researchers may provide new insight into the origins of phagocytosis, the process by which single-celled organisms “eat” other cells as a means of absorbing nutrients or eliminating pathogens.READ MORE
‘Lipid Asymmetry’ Plays Key Role in Activating Immune CellsNews
Regulating the lipid and physical asymmetry of a cell’s membrane is critical to immune cell function, and researchers have now shown that by preventing loss of membrane asymmetry it’s possible to control the immune response.READ MORE
Comments | 0 ADD COMMENT
World Advanced Therapies & Regenerative Medicine Congress
May 16 - May 18, 2018